This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, W. M.
Right arrow Articles by Wohl, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, W. M.
Right arrow Articles by Wohl, M. E.
Related Collections
Right arrow Respiratory Tract

PEDIATRICS Vol. 100 No. 2 August 1997, pp. 205-209

End-of-Life Care in Cystic Fibrosis

Received Dec 18, 1995; accepted Jun 26, 1996.

Walter M. Robinson*, Dagger , Sophie Ravilly*, Dagger , Charles BerdeDagger , §, and Mary Ellen Wohl*, Dagger

From the * Division of Pulmonary Medicine and the Departments of Dagger  Pediatrics and § Anesthesia, Children's Hospital and Harvard Medical School, Boston, Massachusetts.

Objective.  End-of-life clinical care in cystic fibrosis (CF) differs substantially from terminal care in childhood cancer. To examine this difference, we reviewed the medical care of a cohort of CF patients treated at Children's Hospital, Boston, to document the use of preventive, therapeutic, and palliative care in the month preceding death.

Patients.  We reviewed the medical records of 44 patients older than 5 years who died of CF-related respiratory failure for the years 1984 to 1993.

Results.  Thirty-eight patients (86%) received opiates for the treatment of severe dyspnea and pain; the duration of opiate use varied from less than 1 hour to greater than 1 month. The dose of opiates varied from less than 5 mg per hour to greater than 30 mg per hour. Thirty-three patients (75%) continued to receive intravenous antibiotics in the last 12 hours of life; 32 (72%) continued to receive preventive or therapeutic oral medications in the last 12 hours of life. All patients were designated as do not resuscitate at the time of death; 43 of the patients died in the hospital with 1 patient dying at home under hospice care.

Conclusions.  The model of comfort care developed in childhood cancer does not adequately describe the combination of preventive, therapeutic, and palliative care given at the end of life for CF at our institution. The majority of CF patients continued to receive intravenous antibiotics and/or oral vitamin preparations while being treated with opiates for terminal pain and dyspnea. Small doses of opiates seem to be effective in the treatment of the pain and dyspnea at the end of life in CF.

Key words: cystic fibrosis, palliative care, terminal care.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. N. Lanken, P. B. Terry, H. M. DeLisser, B. F. Fahy, J. Hansen-Flaschen, J. E. Heffner, M. Levy, R. A. Mularski, M. L. Osborne, T. J. Prendergast, et al.
An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 912 - 927.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
C. H. Goss and A. L. Quittner
Patient-reported Outcomes in Cystic Fibrosis
Proceedings of the ATS, August 1, 2007; 4(4): 378 - 386.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. EthicsHome page
P. Ramnarayan, F. Craig, A. Petros, and C. Pierce
Characteristics of deaths occurring in hospitalised children: changing trends
J. Med. Ethics, May 1, 2007; 33(5): 255 - 260.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. R. Freyer
Care of the Dying Adolescent: Special Considerations
Pediatrics, February 1, 2004; 113(2): 381 - 388.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. Feudtner, D. A. Christakis, F. J. Zimmerman, J. H. Muldoon, J. M. Neff, and T. D. Koepsell
Characteristics of Deaths Occurring in Children's Hospitals: Implications for Supportive Care Services
Pediatrics, May 1, 2002; 109(5): 887 - 893.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Mitchell, E. Nakielna, E. Tullis, and C. Adair
Cystic Fibrosis : End-Stage Care in Canada
Chest, July 1, 2000; 118(1): 80 - 84.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Wolfe, H. E. Grier, N. Klar, S. B. Levin, J. M. Ellenbogen, S. Salem-Schatz, E. J. Emanuel, and J. C. Weeks
Symptoms and Suffering at the End of Life in Children with Cancer
N. Engl. J. Med., February 3, 2000; 342(5): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. T. R. Westwood;, W. M. Robinson, S. Ravilly, C. Berde, and M. E. Wohl
Terminal Care in Cystic Fibrosis: Hospital Versus Home?
Pediatrics, August 1, 1998; 102(2): 436 - 437.
[Full Text] [PDF]